L1920

LY255283

≥98% (HPLC), powder

• Synonym(e): 1-(5-Ethyl-2-hydroxy-4-(6-methyl-6-(1H-tetrazol-5-yl)heptyloxy)phenyl)ethanone
• Empirische Formel (Hill-System): C₁₉H₂₈N₄O₃
• CAS-Nummer: 117690-79-6
• Molekulargewicht: 360.45
• MDL-Nummer: MFCD00876422
• UNSPSC-Code: 12352204
• PubChem Substanz-ID: 329817396
• NACRES: NA.77

Eigenschaften

• Qualitätsniveau: 100
• Assay: ≥98% (HPLC)
• Form: powder
• Farbe: off-white to light yellow
• Löslichkeit: DMSO: >20 mg/mL
• Ersteller: Eli Lilly
• Lagertemp.: −20°C
• SMILES String: CCc1cc(C(C)=O)c(O)cc1OCCCCCC(C)(C)c2nnn[nH]2
• InChI: 1S/C19H28N4O3/c1-5-14-11-15(13(2)24)16(25)12-17(14)26-10-8-6-7-9-19(3,4)18-20-22-23-21-18/h11-12,25H,5-10H2,1-4H3,(H,20,21,22,23)
• InChIKey: WCGXJPFHTHQNJL-UHFFFAOYSA-N

Beschreibung

Anwendung

LY255283, a competitive leukotriene B4 receptor antagonist, is used in leukotriene receptor research along with other selective leukotriene receptor agonists and antagonist to identify and differentiate the physiological and cell signaling effects of the leukotriene B4 receptor on processes such as paclitaxel resistance in MCF-7/DOX breast cancer cells, monocyte-derived dendritic cell chemotaxis, and 5-lipoxygenase activity and interleukin-8 production in human neutrophils. LY255283 may be used to help verify that an observed process or cell event is leukotriene B4 receptor-dependent.

Biochem./physiol. Wirkung

LY255283 is a competitive leukotriene B₄ receptor antagonist, with an IC₅₀ of about 100 nM. It is somewhat selective for the BLT2 receptor, since IC₅₀ values at the BLT1 receptor are >10 μM. LY255283 reduces airway obstruction in animal models of asthma.

Leistungsmerkmale und Vorteile

This compound was developed by Eli Lilly. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Sicherheitshinweise

• Lagerklassenschlüssel: 11 - Combustible Solids
• WGK: WGK 2
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable